Fingerprint
Dive into the research topics where Bora Lim is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
Delineating the copy-number substructure of metastatic tumors with CopyKit
Wang, J., Minussi, D. C., Davis, A., Wei, R., Ye, H., Sei, E., Schalck, A., Yan, Y., Wu, H. J., Bai, S., Peng, C., Hu, M., Casasent, A., Contreras, A., Chen, H., Hui, D., Damodaran, S., Edgerton, M. E., Kopetz, S. & Lim, B. & 1 others, , Jan 22 2026, In: Molecular cell. 86, 2, p. 407-422.e6Research output: Contribution to journal › Article › peer-review
-
Functional, Pharmacogenomic, and Immune Landscapes of Long Non-Coding RNAs in Cancer
Wang, R., Luo, M., Liu, Y., Yang, J., Chen, Y., Chen, C., Ma, L., Ding, S., Wengler, J., Zang, Y., Lim, B., Li, W., Yang, L., Lin, C., Diao, L. & Han, L., Jan 30 2026, In: Advanced Science. 13, 6, e13414.Research output: Contribution to journal › Article › peer-review
Open Access -
Retrospective review of metastatic hormone receptor-positive inflammatory breast cancer patients reveals poor responses to cyclin dependent kinase 4/6 inhibition
MDACC IBC Clinic and Research Team, Dec 2026, In: Breast Cancer Research. 28, 1, 8.Research output: Contribution to journal › Article › peer-review
Open Access1 Link opens in a new tab Scopus citations -
Tumor microenvironment transcriptional activity enables robust stratification of chemotherapy response in triple-negative breast cancer
Dai, Y., Pan, X., Guo, S., Ji, S., Cao, S., Montierth, M. D., Jiang, Y., Chang, J. T., Shi, L., Shalapour, S., Echeverria, G. V., Yates, L., Staaf, J., Lim, B., Yuan, Y. & Wang, W., Feb 17 2026, In: Cell Reports Medicine. 7, 2, p. 102610 1 p.Research output: Contribution to journal › Article › peer-review
Open Access -
A phase Ib/II trial of neoadjuvant neratinib added to standard therapy in patients with HER2-positive or HR-positive/HER2-negative inflammatory breast cancer (including stage III and IV disease)
MDACC Inflammatory Breast Cancer Team, Oct 1 2025, In: Therapeutic Advances in Medical Oncology. 17, 17588359251379392.Research output: Contribution to journal › Article › peer-review
Open Access